QMS Medical

- The acquisition funding will be through a combination of internal accruals and bank funding. - There is a possibility of a capital increase if approved by the board. - The company has applied with NSE regarding the capital increase. - If approved, they may explore certain ways and means for the capital increase. - The primary approach remains internal accrual and bank funding. - No immediate plans for other acquisitions or fundraising at this moment; focus is on consolidating current acquisition.

- Current capital expenditures have been made primarily for patient service program equipment, such as diabetic retinopathy machines and BMD machines costing between ₹5-8 lakhs each, with an average equipment worth ₹15-16 lakhs per resource. - The company expects to recover this capex within a year based on current operations; equipment lifespan is about 6-7 years. - A recent acquisition of Saarathi Healthcare Services Pvt. Ltd. and Prometheus Healthcare Pvt. Ltd. represents a strategic investment aimed at expanding patient service programs and entering new customer segments. - The acquisition was funded through a mix of internal accruals and bank funding, with possible capital increase pending board approval. - No additional acquisitions or major capital investments are planned immediately; focus will be on consolidating current investments and growing the acquired business over the next year. - The company plans to increase the camp operations capacity by adding 18 more personnel and expanding service offerings post-January after Saarathi integration.

- The company targets a steady revenue growth of around 15-20% annually over the next five years. - Focus on doubling service business revenue, aiming to cross ₹50 Crores within 2-3 years from the current ₹14-15 Crores. - Camp business expansion is a key growth driver, with plans to increase daily camps (currently ~75/day), utilizing 65-70% of capacity. - Growth driven by patient service programs (PSP) and integration with Saarathi post-acquisition, targeting a greater customer base and service expansion. - Traditional medical device distribution (~₹100 Crores business) expected to grow steadily, providing a stable revenue base. - Innovation through new product launches, digital marketing (Qdevices with brand ambassador Kapil Dev), and expanding service offerings. - Consolidation post-acquisition prioritized for the next year before considering further acquisitions or expansions.

- The company targets a steady revenue growth of around 15-20% annually over the next five years. - EBITDA margins are expected to be maintained or slightly improved with a current level around 17-18%. - Patient Service Program (PSP) and service businesses are seen as key growth and profitability drivers, with expectations to double service business revenue to over ₹50 Crores in 2-3 years. - Recent acquisitions (Saarathi, Prometheus) are expected to expand customer base and contribute significantly to profitability from FY2025 onwards. - EPS showed strong growth in H1 FY2024 (from 1.53 to 2.81), signaling robust profitability improvement. - The company intends to consolidate current acquisitions for at least one year before considering further acquisitions, focusing on growth and margin improvement. - Traditional device business (~₹100 Crores) will remain steady, contributing reliable revenue and margins (9-10 Crores EBITDA).

- The company operates mainly on purchase orders basis rather than long-term contracts. - For the product category, contracts are typically single purchase orders for a specified quantity and duration (e.g., one month delivery of 5,000 to 10,000 units). - There are no yearly contracts in the product segment; however, the service business does have ongoing contracts for camps and service programs. - Repeat orders are common, occurring about 10-15% of the time. - No explicit mention of current or expected orderbook value or pending orders was provided in the transcript. - Focus remains on growing service business, including recent acquisitions to increase customer base.